Targets › EDNRA
8 programs from 8 companies in 20 trials: 9 Phase 3, 8 Phase 2, 3 Phase 4; Genitourinary, Cardiovascular, Neurology; next expected readout Jan 2027.
Receptor for endothelin-1. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. (UniProt, P25101)
Open in Phaseline: the race on EDNRA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Travere Therapeutics | Sparsentan Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist | EDNRA, AGTR1 | Phase 4 | Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated Vasculitis | Mar 2027 |
| Johnson & Johnson (Janssen) | Macitentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 3 | Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Combined Pre- and Post-capillary Pulmonary Hypertension | Jan 2027 |
| University Hospital, Grenoble | bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 3 | Ischemic Optic Neuropathy | Feb 2027 |
| AstraZeneca | Zibotentan Endothelin receptor ET-A antagonist | EDNRA | Phase 3 | Chronic Kidney Disease With High Proteinuria | Feb 2027 |
| Novartis | Atrasentan Endothelin receptor ET-A antagonist | EDNRA | Phase 3 | IgA Nephropathy; Berger Disease | Apr 2028 |
| University of Edinburgh | Bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Large Vessel Vasculitis | Jul 2027 |
| Noorik Biopharmaceuticals | Ambrisentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Hepatorenal Syndrome; IgA Nephropathy; Pulmonary Arterial Hypertension (PAH) | – |
| University Hospital, Rouen | Bosentan Endothelin receptor, ET-A/ET-B antagonist | EDNRB, EDNRA | Phase 2 | Resistant Hypertension | – |
IgA Nephropathy (3) Immunoglobulin A Nephropathy (2) Chronic Kidney Disease With High Proteinuria (2) Hypertension, Pulmonary (2) Ischemic Optic Neuropathy (1) Berger Disease (1) Proteinuria (1) Focal Segmental Glomerulosclerosis (1) ANCA Associated Vasculitis (1) Hepatorenal Syndrome (1) Pulmonary Arterial Hypertension (PAH) (1) Resistant Hypertension (1)
small molecule (7), mixed (1)
University Hospital, Grenoble (1) Novartis (1) Travere Therapeutics (1) AstraZeneca (1) Noorik Biopharmaceuticals (1) University Hospital, Rouen (1) University of Edinburgh (1) Johnson & Johnson (Janssen) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.